Travere Therapeutics (TVTX) said Wednesday it has completed a public offering of 9.0 million shares of common stock at a price to the public of $16.00 per share, including 1.2 million shares sold as part of the underwriters' option to purchase additional shares, for gross proceeds of around $143.8 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。